CTI opens new offices to support anticipated demand for regenerative medicine expertise

11-Jun-2019 - Last updated on 11-Jun-2019 at 14:26 GMT

(Image: Getty/Ankabala)

The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.

CTI Clinical Trial and Consulting Services (CTI), contract research organization (CRO) headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific.

The company today announced the opening of new offices in Dallas, TX and San Diego, CA.

“We chose Dallas and San Diego because of the talent pool and other resources we see in those communities and the opportunities they present for both CTI and our pharmaceutical and biotechnology sponsors,” said Timothy Schroeder, CTI founder and CEO.

Schroeder said the specific job functions in the new offices will vary and include different clinical operations positions, with the services to be the same as the company’s other offices.

Several employees have already been hired at each office and more expected to be added in the coming months. “The rate of growth will be driven by the quality of the candidates,” explained Schroeder.

“In the past several years, we have seen significant growth from the pharmaceutical/biotechnology industry in the areas of cell and gene therapies, especially in rare diseases and immune-oncology,” he added.

Schroeder said, “As we’ve been working in the field since before it had a name, we anticipate demand for our regenerative medicine expertise to continue to increase.”

In line with this, the company in April doubled its footprint in Raleigh, NC and moved its West Coast office in San Francisco to a larger space.